Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 16, 2026
Context: This filing reports on the execution of a share repurchase programme initiated on February 4, 2026. Novo Nordisk is a global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries.
Key Financial Metrics
Share Repurchase Programme:
- Total Programme Size: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Current Sub-Programme: Up to DKK 3.8 billion for the period February 4, 2026, to May 4, 2026.
- Shares Repurchased (Feb 4 - Mar 13, 2026): 6,577,992 B shares.
- Total Transaction Value: DKK 1,783,540,174.
- Average Purchase Price: DKK 271.14 per B share.
- Total Treasury Shares Held: 23,967,791 B shares.
- Percentage of Share Capital: 0.5%.
- Total Outstanding Shares (A and B): 4,465,000,000 (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Recent Activity (March 9 - March 13, 2026):
- Repurchased 1,243,000 B shares across five trading days.
- Daily transaction values ranged from approximately DKK 61.5 million to DKK 62.4 million.
- Daily average purchase prices ranged from DKK 248.83 to DKK 251.47.
The filing does not provide comparative financial data for prior periods to assess material changes in operating performance.
Guidance, Outlook, and Risks
Outlook:
- Novo Nordisk expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period beginning February 4, 2026.
- The company reaffirms its purpose to drive change to defeat serious chronic diseases, built upon its heritage in diabetes.
- The filing does not explicitly detail new risks or contingencies beyond the standard execution of the share buyback under EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
- No unusual items were reported in this filing.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 15 billion share repurchase programme.
- Confirm the current market price of Novo Nordisk B shares relative to the average repurchase price of DKK 271.14.
- Review the full list of daily transactions on the company's official website (novonordisk.com) for granular data.
- Check subsequent filings for updates on the total treasury share count and percentage of share capital.